StockData
ELI LILLY & Co logo

ELI LILLY & Co (LLY) operating KPIs

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)

Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%

Eli Lilly mounjaro (tirzepatide — Type 2 diabetes & international obesity) — Worldwide revenue ($M) ($M)

Form 10-Q / 10-K Note 2, MD&A & Form 8-K Earnings Releases

QuarterlyAnnual
Latest, Q2 2026
9,943
Period ended Jun 30, 2026
Change on a year earlier
+91.2%
5,199 in Q2 2025
History
19 quarters
Since Q3 2021
Sources
16
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedMounjaro (tirzepatide — Type 2 diabetes & international obesity) — Worldwide revenue ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20269,943+91.2%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 20268,662+125.5%Form 10-Q (filed 2026-04-30) ↗
Q4 2025Dec 31, 20257,409+109.9%Earnings Release (Form 8-K FY2025Q4 EX-99.1) (filed 2026-02-04) ↗
Q3 2025Sep 30, 20256,515+109.3%Form 10-Q (filed 2025-10-30) ↗
Q2 2025Jun 30, 20255,199+68.2%Form 10-Q (filed 2026-08-05) ↗
Q1 2025Mar 31, 20253,842+112.7%Form 10-Q (filed 2026-04-30) ↗
Q4 2024Dec 31, 20243,530+60.1%Earnings Release (Form 8-K FY2024Q4 EX-99.1) (filed 2025-02-06) ↗
Q3 2024Sep 30, 20243,113+120.9%Form 10-Q (filed 2025-10-30) ↗
Q2 2024Jun 30, 20243,091+215.5%Form 10-Q (filed 2025-08-07) ↗
Q1 2024Mar 31, 20241,807+217.8%Form 10-Q (filed 2025-05-01) ↗
Q4 2023Dec 31, 20232,206+690.0%Earnings Release (Form 8-K FY2023Q4 EX-99.1) (filed 2024-02-06) ↗
Q3 2023Sep 30, 20231,409+652.4%Form 10-Q (filed 2024-10-30) ↗
Q2 2023Jun 30, 2023980+6,023.1%Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 2023569–Form 10-Q (filed 2024-04-30) ↗
Q4 2022Dec 31, 2022279–Earnings Release (Form 8-K FY2022Q4 EX-99.1) (filed 2023-02-02) ↗
Q3 2022Sep 30, 2022187–Form 10-Q (filed 2023-11-02) ↗

Breakdown

What makes up mounjaro (tirzepatide — type 2 diabetes & international obesity) — worldwide revenue ($m)

Cite this data

StockData. (2026). Eli Lilly Mounjaro (tirzepatide — Type 2 diabetes & international obesity) — Worldwide revenue ($M) ($M), quarterly Q3 2021–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_mounjaro_ww

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.